Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Stellar Biotechnologies Provides Quarterly Update/Outlook and Comments on CBS News Cancer Vaccine Story

Abstract:
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (PINKSHEETS: SBOTF) has been advancing on several fronts over their first quarter as a public company, and expects to achieve new milestones before year end.

Stellar Biotechnologies Provides Quarterly Update/Outlook and Comments on CBS News Cancer Vaccine Story

Port Hueneme, CA | Posted on October 13th, 2010

The Company would like to comment on the recent, featured CBS Evening News report (see video link below) by Dr. Sanjay Gupta on a KLH-based glioblastoma vaccine in development by Celldex Therapeutics about which it has received enquiries.

On October 4th CBS Evening News with Katie Couric featured Dr. Sanjay Gupta in a story about a KLH-based brain cancer vaccine being tested in patients at Duke University for Celldex Therapeutics (*).

John S. Sundsmo, Ph.D., Stellar's VP of Research & Intellectual Property Management, said "Molecular biology is identifying genetic modifications in certain cancer cells that constitute targets for cancer vaccines. Dr. Sanjay Gupta discusses the initial successes observed with glioblastoma multiforme (GBM), normally a rapidly progressing form of brain cancer. The cancer vaccine in the report was produced by Celldex Therapeutics by coupling a cancer-specific protein onto the immune carrier protein KLH. The very early stage results for some patients show signs in MRIs that their tumors may have decreased. While the immune system is highly effective in protecting us against bacteria, cancer cells are extremely difficult to kill and effective killing is mediated by a specialized class of killer T-cells. In this respect, KLH, the hemocyanin protein from the giant keyhole limpet, can be seen as rather unique. KLH stimulates highly effective cell-mediated immunity that results in the production of cancer-killing T-cells. This is offering new hope for patients with previously incurable cancers." Discussions between Celldex and Stellar have been underway.

Quarterly Update/Outlook

Achievements

• On September 9th Stellar announced that it had filed for patent protection of inventions related to its Immunogenic (IMG) KLH technology platforms (1)
• On September 13th the Company announced a milestone payment from Bayer Innovation (a wholly owned subsidiary of international pharmaceutical company, Bayer AG: (PINKSHEETS: BAYRY) and the achievement of a critical milestone in our Joint Development Agreement (2)
• On September 29th Stellar disclosed a CDN $1.05M private placement with a strategic investor and the retirement of 1.66 million shares to the treasury (3)
• On September 30th the Company announced receipt of $288,000 from a single biotechnology and immunotherapy products company developing KLH-based therapeutic vaccines for Rheumatoid Arthritis and Lupus for fiscal year ending August 30, 2010 (4)

2010 Outlook

• first Annual General Meeting since public
• status of grants that have been applied for by Stellar's California subsidiary
• launch date for sales of immunotox products aimed at the pre-clinical market, related to our ongoing research designed to advance Stellar's immune response diagnostic platform
• research and regulatory developments related to our new IMG KLH product platform
• advancements related to our relationships with Bayer Innovation and several new customers
• in and out-licensing and long-term supply agreements, as well as new KLH orders.

(*) (3 minute video: www.cbsnews.com/video/watch/?id=6927121n&tag=related;photovideo
a short article here: www.acsh.org/factsfears/newsID.1920/news_detail.asp)

(1) www.stellarbiotechnologies.com/investors/news_releases/index.php?&content_id=43
(2) www.stellarbiotechnologies.com/investors/news_releases/index.php?&content_id=44
(3) www.stellarbiotechnologies.com/investors/news_releases/index.php?&content_id=45
(4) www.stellarbiotechnologies.com/investors/news_releases/index.php?&content_id=46


Statements in these press releases other than purely historical factual information, including statements relating to revenues or profits, or the Company's future plans and objectives, or expected sales, cash flows, and capital expenditures constitute forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business, including risks inherent in the technology history. There can be no assurance that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. These news releases do not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.

####

About Stellar Biotechnologies
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This ancient evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.

For more information, please click here

Contacts:
Darrell Brookstein, Executive VP, Business Development & Finance

Copyright © Stellar Biotechnologies

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Silicene Labs Announces the Launch of Patent-Pending, 2D Materials Composite Index™ : The Initial 2D Materials Composite Index™ for Q2 2014 Is: 857.3; Founders Include World-Renowned Physicist and Seasoned Business and IP Professionals July 24th, 2014

Iranian Scientists Produce Transparent Nanocomposite Coatings with Longer Lifetime July 24th, 2014

Deadline Announced for Registration in 7th Int'l Nanotechnology Festival in Iran July 23rd, 2014

A Crystal Wedding in the Nanocosmos July 23rd, 2014

Nanomedicine

Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014

NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014

SentiMag® Now Available in Australia and New Zealand July 21st, 2014

More than glitter: Scientists explain how gold nanoparticles easily penetrate cells, making them useful for delivering drugs July 21st, 2014

Announcements

Silicene Labs Announces the Launch of Patent-Pending, 2D Materials Composite Index™ : The Initial 2D Materials Composite Index™ for Q2 2014 Is: 857.3; Founders Include World-Renowned Physicist and Seasoned Business and IP Professionals July 24th, 2014

Iranian Scientists Produce Transparent Nanocomposite Coatings with Longer Lifetime July 24th, 2014

Deadline Announced for Registration in 7th Int'l Nanotechnology Festival in Iran July 23rd, 2014

A Crystal Wedding in the Nanocosmos July 23rd, 2014

Patents/IP/Tech Transfer/Licensing

Silicene Labs Announces the Launch of Patent-Pending, 2D Materials Composite Index™ : The Initial 2D Materials Composite Index™ for Q2 2014 Is: 857.3; Founders Include World-Renowned Physicist and Seasoned Business and IP Professionals July 24th, 2014

UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014

Bruker Awarded Fourth PeakForce Tapping Patent: AFM Mode Uniquely Combines Highest Resolution Imaging and Material Property Mapping July 22nd, 2014

Rice's silicon oxide memories catch manufacturers' eye: Use of porous silicon oxide reduces forming voltage, improves manufacturability July 10th, 2014

Financial Reports

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014

Aspen Aerogels, Inc. Schedules Second Quarter 2014 Earnings Release and Conference Call July 15th, 2014

Nanometrics to Announce Second Quarter Financial Results on July 30, 2014 July 9th, 2014

Small, but heading for the big time: Nanobiotix revenue for the 1st quarter of 2014 and new composition of the shareholding May 12th, 2014

Nanobiotechnology

Production of Non-Virus Nanocarriers with Highest Amount of Gene Delivery July 17th, 2014

Physicists Use Computer Models to Reveal Quantum Effects in Biological Oxygen Transport: The team solved a long-standing question by explaining why oxygen – and not deadly carbon monoxide – preferably binds to the proteins that transport it around the body. July 17th, 2014

Tiny DNA pyramids enter bacteria easily -- and deliver a deadly payload July 9th, 2014

Artificial cilia: Scientists from Kiel University develop nano-structured transportation system July 4th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE